JP2007084552A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007084552A5 JP2007084552A5 JP2006283861A JP2006283861A JP2007084552A5 JP 2007084552 A5 JP2007084552 A5 JP 2007084552A5 JP 2006283861 A JP2006283861 A JP 2006283861A JP 2006283861 A JP2006283861 A JP 2006283861A JP 2007084552 A5 JP2007084552 A5 JP 2007084552A5
- Authority
- JP
- Japan
- Prior art keywords
- phenylpropyl
- diisopropylamino
- acid
- ester
- nmr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000005481 NMR spectroscopy Methods 0.000 description 113
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 83
- -1 benzoylacyl Chemical group 0.000 description 77
- 150000001875 compounds Chemical class 0.000 description 76
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 63
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 57
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 57
- 239000000243 solution Substances 0.000 description 57
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 54
- 239000000543 intermediate Substances 0.000 description 54
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 47
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 42
- 239000000203 mixture Substances 0.000 description 39
- 238000002844 melting Methods 0.000 description 35
- 230000008018 melting Effects 0.000 description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 34
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 32
- 239000007787 solid Substances 0.000 description 30
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 28
- 239000007858 starting material Substances 0.000 description 27
- 150000002148 esters Chemical class 0.000 description 26
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 25
- 238000000034 method Methods 0.000 description 25
- 239000003921 oil Substances 0.000 description 25
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 24
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 23
- 238000006243 chemical reaction Methods 0.000 description 21
- 229910052739 hydrogen Inorganic materials 0.000 description 20
- 150000003839 salts Chemical class 0.000 description 20
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- 239000001257 hydrogen Substances 0.000 description 18
- 239000002904 solvent Substances 0.000 description 17
- 239000002253 acid Substances 0.000 description 16
- 230000003287 optical effect Effects 0.000 description 16
- 238000003756 stirring Methods 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 15
- 239000012230 colorless oil Substances 0.000 description 15
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 15
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 14
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
- 229910021529 ammonia Inorganic materials 0.000 description 14
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 14
- 125000001743 benzylic group Chemical group 0.000 description 13
- 238000001816 cooling Methods 0.000 description 13
- 150000005690 diesters Chemical class 0.000 description 13
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 13
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 13
- 239000012074 organic phase Substances 0.000 description 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 125000000217 alkyl group Chemical group 0.000 description 12
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- 229910052757 nitrogen Inorganic materials 0.000 description 12
- 125000000026 trimethylsilyl group Chemical class [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 12
- 239000013078 crystal Substances 0.000 description 11
- 150000002431 hydrogen Chemical class 0.000 description 11
- 229910052938 sodium sulfate Inorganic materials 0.000 description 11
- 235000011152 sodium sulphate Nutrition 0.000 description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- 239000002585 base Substances 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 239000002244 precipitate Substances 0.000 description 10
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 description 10
- KISZTEOELCMZPY-UHFFFAOYSA-N 3,3-diphenylpropylamine Chemical class C=1C=CC=CC=1C(CCN)C1=CC=CC=C1 KISZTEOELCMZPY-UHFFFAOYSA-N 0.000 description 9
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 9
- 125000003118 aryl group Chemical group 0.000 description 9
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 9
- 238000001704 evaporation Methods 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 239000002207 metabolite Substances 0.000 description 9
- 239000006188 syrup Substances 0.000 description 9
- 235000020357 syrup Nutrition 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 8
- 125000001424 substituent group Chemical group 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 229960004045 tolterodine Drugs 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 description 8
- DUXZAXCGJSBGDW-UHFFFAOYSA-N 2-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenol Chemical compound C=1C(CO)=CC=C(O)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 DUXZAXCGJSBGDW-UHFFFAOYSA-N 0.000 description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 7
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 239000012299 nitrogen atmosphere Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 235000017557 sodium bicarbonate Nutrition 0.000 description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 230000001022 anti-muscarinic effect Effects 0.000 description 6
- 239000003054 catalyst Substances 0.000 description 6
- 229920001577 copolymer Polymers 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 230000008020 evaporation Effects 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 150000004702 methyl esters Chemical class 0.000 description 6
- 229960005434 oxybutynin Drugs 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 229940002612 prodrug Drugs 0.000 description 6
- 239000000651 prodrug Substances 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 5
- 0 CC(C)*(CCC(c1ccccc1)c1cc(C(*)(N)IC)ccc1ClC(*(*)=C)=O)C(C)C Chemical compound CC(C)*(CCC(c1ccccc1)c1cc(C(*)(N)IC)ccc1ClC(*(*)=C)=O)C(C)C 0.000 description 5
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 5
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 239000012298 atmosphere Substances 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 238000009835 boiling Methods 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 125000001183 hydrocarbyl group Chemical group 0.000 description 5
- 150000007522 mineralic acids Chemical class 0.000 description 5
- 239000003149 muscarinic antagonist Substances 0.000 description 5
- 238000010791 quenching Methods 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 239000011877 solvent mixture Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 description 4
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 description 4
- IFBPJCUUTXMZLB-UHFFFAOYSA-N 3-(5-bromo-2-phenylmethoxyphenyl)-3-phenylpropanoic acid Chemical compound C=1C(Br)=CC=C(OCC=2C=CC=CC=2)C=1C(CC(=O)O)C1=CC=CC=C1 IFBPJCUUTXMZLB-UHFFFAOYSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 4
- 108090001060 Lipase Proteins 0.000 description 4
- 102000004882 Lipase Human genes 0.000 description 4
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 4
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 4
- 208000000921 Urge Urinary Incontinence Diseases 0.000 description 4
- KGNKBMFLHKBDSX-UHFFFAOYSA-N [2-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl] benzoate Chemical compound C=1C(CO)=CC=C(OC(=O)C=2C=CC=CC=2)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 KGNKBMFLHKBDSX-UHFFFAOYSA-N 0.000 description 4
- 238000005917 acylation reaction Methods 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 4
- 125000000837 carbohydrate group Chemical group 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 230000008602 contraction Effects 0.000 description 4
- 125000000753 cycloalkyl group Chemical group 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 229910001873 dinitrogen Inorganic materials 0.000 description 4
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000003818 flash chromatography Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- 238000005227 gel permeation chromatography Methods 0.000 description 4
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000012280 lithium aluminium hydride Substances 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- MSJGQLPLCOBFNR-CSKARUKUSA-N methyl 3-[(e)-3-[di(propan-2-yl)amino]-3-oxoprop-1-enyl]-4-methoxybenzoate Chemical compound COC(=O)C1=CC=C(OC)C(\C=C\C(=O)N(C(C)C)C(C)C)=C1 MSJGQLPLCOBFNR-CSKARUKUSA-N 0.000 description 4
- YHOSNAAUPKDRMI-UHFFFAOYSA-N n,n-di(propan-2-yl)prop-2-enamide Chemical compound CC(C)N(C(C)C)C(=O)C=C YHOSNAAUPKDRMI-UHFFFAOYSA-N 0.000 description 4
- BVJSUAQZOZWCKN-UHFFFAOYSA-N p-hydroxybenzyl alcohol Chemical compound OCC1=CC=C(O)C=C1 BVJSUAQZOZWCKN-UHFFFAOYSA-N 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 4
- 230000007306 turnover Effects 0.000 description 4
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 3
- 102000017925 CHRM3 Human genes 0.000 description 3
- 101150060249 CHRM3 gene Proteins 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 239000004367 Lipase Substances 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 206010046543 Urinary incontinence Diseases 0.000 description 3
- DBAAHIYZQIIMAH-UHFFFAOYSA-N [3-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-pent-4-enoyloxyphenyl]methyl pent-4-enoate Chemical compound C=1C(COC(=O)CCC=C)=CC=C(OC(=O)CCC=C)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 DBAAHIYZQIIMAH-UHFFFAOYSA-N 0.000 description 3
- KBQJPVIJGZHINT-UHFFFAOYSA-N [3-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-phenylmethoxyphenyl]methyl benzoate Chemical compound C=1C(COC(=O)C=2C=CC=CC=2)=CC=C(OCC=2C=CC=CC=2)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 KBQJPVIJGZHINT-UHFFFAOYSA-N 0.000 description 3
- ZYYOQPPGPQQGCU-UHFFFAOYSA-N [4-(acetyloxymethyl)-2-[3-[di(propan-2-yl)amino]-1-phenylpropyl]phenyl] 2-methylpropanoate Chemical compound C=1C(COC(C)=O)=CC=C(OC(=O)C(C)C)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 ZYYOQPPGPQQGCU-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000010933 acylation Effects 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 3
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 229910052805 deuterium Inorganic materials 0.000 description 3
- 229940043279 diisopropylamine Drugs 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 150000004820 halides Chemical class 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 238000007327 hydrogenolysis reaction Methods 0.000 description 3
- 239000012442 inert solvent Substances 0.000 description 3
- 239000012948 isocyanate Substances 0.000 description 3
- 150000002513 isocyanates Chemical class 0.000 description 3
- 235000019421 lipase Nutrition 0.000 description 3
- LJDGPIHWEJMCHJ-UHFFFAOYSA-N methyl 3-[3-[di(propan-2-yl)amino]-3-oxo-1-phenylpropyl]-4-methoxybenzoate Chemical compound COC(=O)C1=CC=C(OC)C(C(CC(=O)N(C(C)C)C(C)C)C=2C=CC=CC=2)=C1 LJDGPIHWEJMCHJ-UHFFFAOYSA-N 0.000 description 3
- 229960001383 methylscopolamine Drugs 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 125000001302 tertiary amino group Chemical group 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 206010046494 urge incontinence Diseases 0.000 description 3
- 229920001567 vinyl ester resin Polymers 0.000 description 3
- DQSGCKIKXBUQTJ-UTBFPMLTSA-N (2s,3s,4s,5r,6r)-6-[[3-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-hydroxyphenyl]methoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound C=1C(CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@H](O2)C(O)=O)O)=CC=C(O)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 DQSGCKIKXBUQTJ-UTBFPMLTSA-N 0.000 description 2
- UCYJWCSOSZIQLQ-AREMUKBSSA-N (3r)-3-(5-bromo-2-phenylmethoxyphenyl)-3-phenyl-n,n-di(propan-2-yl)propan-1-amine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(Br)C=2)OCC=2C=CC=CC=2)=CC=CC=C1 UCYJWCSOSZIQLQ-AREMUKBSSA-N 0.000 description 2
- FXZAPECDHLNXCB-UHFFFAOYSA-N (4-bromophenyl) 3-phenylprop-2-enoate Chemical compound C1=CC(Br)=CC=C1OC(=O)C=CC1=CC=CC=C1 FXZAPECDHLNXCB-UHFFFAOYSA-N 0.000 description 2
- VKPPGRKDENBKHV-BFWBPSQCSA-N 2-(dideuteriomethyl)-3-[3-[di(propan-2-yl)amino]-1-phenylpropyl]benzene-1,4-diol Chemical compound C(C)(C)N(CCC(C1=CC=CC=C1)C1=C(C=CC(=C1C([2H])[2H])O)O)C(C)C VKPPGRKDENBKHV-BFWBPSQCSA-N 0.000 description 2
- IOAGZOSRHBAGLF-UHFFFAOYSA-N 2-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(ethoxymethyl)phenol Chemical compound CCOCC1=CC=C(O)C(C(CCN(C(C)C)C(C)C)C=2C=CC=CC=2)=C1 IOAGZOSRHBAGLF-UHFFFAOYSA-N 0.000 description 2
- ICRSOVOKENPWCQ-UHFFFAOYSA-N 2-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(methoxymethyl)phenol Chemical compound COCC1=CC=C(O)C(C(CCN(C(C)C)C(C)C)C=2C=CC=CC=2)=C1 ICRSOVOKENPWCQ-UHFFFAOYSA-N 0.000 description 2
- ZXOAYKHGVAAUQX-UHFFFAOYSA-N 2-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(propan-2-yloxymethyl)phenol Chemical compound CC(C)OCC1=CC=C(O)C(C(CCN(C(C)C)C(C)C)C=2C=CC=CC=2)=C1 ZXOAYKHGVAAUQX-UHFFFAOYSA-N 0.000 description 2
- JZPBSPBDNUCJNY-UHFFFAOYSA-N 2-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(propoxymethyl)phenol Chemical compound CCCOCC1=CC=C(O)C(C(CCN(C(C)C)C(C)C)C=2C=CC=CC=2)=C1 JZPBSPBDNUCJNY-UHFFFAOYSA-N 0.000 description 2
- FVGOMOJXEFTVPO-UHFFFAOYSA-N 2-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(trimethylsilyloxymethyl)phenol Chemical compound C=1C(CO[Si](C)(C)C)=CC=C(O)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 FVGOMOJXEFTVPO-UHFFFAOYSA-N 0.000 description 2
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 2
- KJMCZWJBHWBPNB-UHFFFAOYSA-N 3-(5-bromo-2-phenylmethoxyphenyl)-3-phenylpropan-1-ol Chemical compound C=1C(Br)=CC=C(OCC=2C=CC=CC=2)C=1C(CCO)C1=CC=CC=C1 KJMCZWJBHWBPNB-UHFFFAOYSA-N 0.000 description 2
- KHTAIVJFQGLEFQ-UHFFFAOYSA-N 3-[2-[tert-butyl(dimethyl)silyl]oxy-5-[[tert-butyl(dimethyl)silyl]oxymethyl]phenyl]-3-phenyl-n,n-di(propan-2-yl)propan-1-amine Chemical compound C=1C(CO[Si](C)(C)C(C)(C)C)=CC=C(O[Si](C)(C)C(C)(C)C)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 KHTAIVJFQGLEFQ-UHFFFAOYSA-N 0.000 description 2
- YWQSBJFSXVRFOA-UHFFFAOYSA-N 3-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-phenylmethoxybenzoic acid;hydrochloride Chemical compound Cl.C=1C(C(O)=O)=CC=C(OCC=2C=CC=CC=2)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 YWQSBJFSXVRFOA-UHFFFAOYSA-N 0.000 description 2
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 2
- FEKBGCMJPISLFY-UHFFFAOYSA-N 4-(butoxymethyl)-2-[3-[di(propan-2-yl)amino]-1-phenylpropyl]phenol Chemical compound CCCCOCC1=CC=C(O)C(C(CCN(C(C)C)C(C)C)C=2C=CC=CC=2)=C1 FEKBGCMJPISLFY-UHFFFAOYSA-N 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- LXYOEDGDQBDZFK-UHFFFAOYSA-N 5-bromo-2-phenylmethoxybenzaldehyde Chemical compound O=CC1=CC(Br)=CC=C1OCC1=CC=CC=C1 LXYOEDGDQBDZFK-UHFFFAOYSA-N 0.000 description 2
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N Benzylformate Chemical compound O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- 108090000371 Esterases Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 102000007202 Muscarinic M3 Receptor Human genes 0.000 description 2
- 108010008405 Muscarinic M3 Receptor Proteins 0.000 description 2
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 2
- FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical compound CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 2
- 239000007868 Raney catalyst Substances 0.000 description 2
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
- 229910000564 Raney nickel Inorganic materials 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- YITIBBWTPPPIBU-UHFFFAOYSA-N [2-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(ethoxycarbonyloxymethyl)phenyl] ethyl carbonate Chemical compound CCOC(=O)OCC1=CC=C(OC(=O)OCC)C(C(CCN(C(C)C)C(C)C)C=2C=CC=CC=2)=C1 YITIBBWTPPPIBU-UHFFFAOYSA-N 0.000 description 2
- AXPHWDWOHXSWLO-UHFFFAOYSA-N [2-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(formyloxymethyl)phenyl] acetate Chemical compound C=1C(COC=O)=CC=C(OC(C)=O)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 AXPHWDWOHXSWLO-UHFFFAOYSA-N 0.000 description 2
- CUBIWNOXCQKTST-UHFFFAOYSA-N [2-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(formyloxymethyl)phenyl] benzoate Chemical compound C=1C(COC=O)=CC=C(OC(=O)C=2C=CC=CC=2)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 CUBIWNOXCQKTST-UHFFFAOYSA-N 0.000 description 2
- ORGQWJPFPNJJMJ-UHFFFAOYSA-N [2-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl] 2-acetamidoacetate Chemical compound C=1C(CO)=CC=C(OC(=O)CNC(C)=O)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 ORGQWJPFPNJJMJ-UHFFFAOYSA-N 0.000 description 2
- HQFAUISFJSCISA-UHFFFAOYSA-N [2-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl] 2-acetyloxybenzoate Chemical compound C=1C(CO)=CC=C(OC(=O)C=2C(=CC=CC=2)OC(C)=O)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 HQFAUISFJSCISA-UHFFFAOYSA-N 0.000 description 2
- GGBRJVDMIAIYQE-UHFFFAOYSA-N [2-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl] 2-methoxybenzoate Chemical compound COC1=CC=CC=C1C(=O)OC1=CC=C(CO)C=C1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 GGBRJVDMIAIYQE-UHFFFAOYSA-N 0.000 description 2
- SIVIXAOLMWQGHP-UHFFFAOYSA-N [2-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl] 2-methylbenzoate Chemical compound C=1C(CO)=CC=C(OC(=O)C=2C(=CC=CC=2)C)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 SIVIXAOLMWQGHP-UHFFFAOYSA-N 0.000 description 2
- DCCSDBARQIPTGU-UHFFFAOYSA-N [2-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl] 2-methylpropanoate Chemical compound C=1C(CO)=CC=C(OC(=O)C(C)C)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 DCCSDBARQIPTGU-UHFFFAOYSA-N 0.000 description 2
- NRGLGVDLGIWGQI-UHFFFAOYSA-N [2-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl] 2-nitrobenzoate Chemical compound C=1C(CO)=CC=C(OC(=O)C=2C(=CC=CC=2)[N+]([O-])=O)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 NRGLGVDLGIWGQI-UHFFFAOYSA-N 0.000 description 2
- MBLCIBYXWDJRTL-UHFFFAOYSA-N [2-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl] 4-chlorobenzoate Chemical compound C=1C(CO)=CC=C(OC(=O)C=2C=CC(Cl)=CC=2)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 MBLCIBYXWDJRTL-UHFFFAOYSA-N 0.000 description 2
- CTYLBYQJDFJQHD-UHFFFAOYSA-N [2-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl] 4-methylbenzoate Chemical compound C=1C(CO)=CC=C(OC(=O)C=2C=CC(C)=CC=2)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 CTYLBYQJDFJQHD-UHFFFAOYSA-N 0.000 description 2
- ZQCOFHZGQGRBCO-UHFFFAOYSA-N [2-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl] 4-nitrobenzoate Chemical compound C=1C(CO)=CC=C(OC(=O)C=2C=CC(=CC=2)[N+]([O-])=O)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 ZQCOFHZGQGRBCO-UHFFFAOYSA-N 0.000 description 2
- ZHMZAZQYTLBIMY-UHFFFAOYSA-N [2-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl] butanoate Chemical compound CCCC(=O)OC1=CC=C(CO)C=C1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 ZHMZAZQYTLBIMY-UHFFFAOYSA-N 0.000 description 2
- YGQQSKRWISRYIE-UHFFFAOYSA-N [2-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl] cyclopentanecarboxylate Chemical compound C=1C(CO)=CC=C(OC(=O)C2CCCC2)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 YGQQSKRWISRYIE-UHFFFAOYSA-N 0.000 description 2
- PVZNVGVWHLOLTC-UHFFFAOYSA-N [2-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl] n,n-diethylcarbamate Chemical compound CCN(CC)C(=O)OC1=CC=C(CO)C=C1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 PVZNVGVWHLOLTC-UHFFFAOYSA-N 0.000 description 2
- ZZJSLWQZSGYEPC-UHFFFAOYSA-N [2-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl] n-ethylcarbamate Chemical compound CCNC(=O)OC1=CC=C(CO)C=C1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 ZZJSLWQZSGYEPC-UHFFFAOYSA-N 0.000 description 2
- KVDHKPWDAQUASS-UHFFFAOYSA-N [2-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl] n-phenylcarbamate Chemical compound C=1C(CO)=CC=C(OC(=O)NC=2C=CC=CC=2)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 KVDHKPWDAQUASS-UHFFFAOYSA-N 0.000 description 2
- HKUGDRYPCZTPID-UHFFFAOYSA-N [2-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl] naphthalene-1-carboxylate Chemical compound C=1C(CO)=CC=C(OC(=O)C=2C3=CC=CC=C3C=CC=2)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 HKUGDRYPCZTPID-UHFFFAOYSA-N 0.000 description 2
- MEKUIJXCWXWTDS-UHFFFAOYSA-N [2-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl] naphthalene-2-carboxylate Chemical compound C=1C(CO)=CC=C(OC(=O)C=2C=C3C=CC=CC3=CC=2)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 MEKUIJXCWXWTDS-UHFFFAOYSA-N 0.000 description 2
- KBCRQQPEPOQTFD-UHFFFAOYSA-N [2-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl] propanoate Chemical compound CCC(=O)OC1=CC=C(CO)C=C1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 KBCRQQPEPOQTFD-UHFFFAOYSA-N 0.000 description 2
- HSCRYMUWADSZNR-UHFFFAOYSA-N [2-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(methoxymethyl)phenyl] acetate Chemical compound COCC1=CC=C(OC(C)=O)C(C(CCN(C(C)C)C(C)C)C=2C=CC=CC=2)=C1 HSCRYMUWADSZNR-UHFFFAOYSA-N 0.000 description 2
- WXQIMMHESMEGJT-UHFFFAOYSA-N [3-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(2-methylpropanoyloxy)phenyl]methyl 2-methylpropanoate Chemical compound C=1C(COC(=O)C(C)C)=CC=C(OC(=O)C(C)C)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 WXQIMMHESMEGJT-UHFFFAOYSA-N 0.000 description 2
- FQGQHOIIFPANBW-UHFFFAOYSA-N [3-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-formyloxyphenyl]methyl formate Chemical compound C=1C(COC=O)=CC=C(OC=O)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 FQGQHOIIFPANBW-UHFFFAOYSA-N 0.000 description 2
- UEMMFPSHISRHIK-UHFFFAOYSA-N [3-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-hydroxyphenyl]methyl 2-methylpropanoate Chemical compound C=1C(COC(=O)C(C)C)=CC=C(O)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 UEMMFPSHISRHIK-UHFFFAOYSA-N 0.000 description 2
- MRPQPFZQDZLULY-UHFFFAOYSA-N [3-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-hydroxyphenyl]methyl acetate Chemical compound C=1C(COC(C)=O)=CC=C(O)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 MRPQPFZQDZLULY-UHFFFAOYSA-N 0.000 description 2
- AWSAXDSHDDRXDH-UHFFFAOYSA-N [3-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-hydroxyphenyl]methyl butanoate Chemical compound CCCC(=O)OCC1=CC=C(O)C(C(CCN(C(C)C)C(C)C)C=2C=CC=CC=2)=C1 AWSAXDSHDDRXDH-UHFFFAOYSA-N 0.000 description 2
- FVJZAGORFDOLFR-UHFFFAOYSA-N [3-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-hydroxyphenyl]methyl formate Chemical compound C=1C(COC=O)=CC=C(O)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 FVJZAGORFDOLFR-UHFFFAOYSA-N 0.000 description 2
- DDHZRAZIPFFORZ-UHFFFAOYSA-N [3-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-hydroxyphenyl]methyl propanoate Chemical compound CCC(=O)OCC1=CC=C(O)C(C(CCN(C(C)C)C(C)C)C=2C=CC=CC=2)=C1 DDHZRAZIPFFORZ-UHFFFAOYSA-N 0.000 description 2
- GVKBRMPULOEHLO-UHFFFAOYSA-N [3-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-phenylmethoxyphenyl]methanol Chemical compound C=1C(CO)=CC=C(OCC=2C=CC=CC=2)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 GVKBRMPULOEHLO-UHFFFAOYSA-N 0.000 description 2
- IDYNFCRMUDQBTD-UHFFFAOYSA-N [3-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-phenylmethoxyphenyl]methyl acetate Chemical compound C=1C(COC(C)=O)=CC=C(OCC=2C=CC=CC=2)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 IDYNFCRMUDQBTD-UHFFFAOYSA-N 0.000 description 2
- AWTGTSYTZIFAQF-UHFFFAOYSA-N [4-(acetyloxymethyl)-2-[3-[di(propan-2-yl)amino]-1-phenylpropyl]phenyl] 2,2-dimethylpropanoate Chemical compound C=1C(COC(C)=O)=CC=C(OC(=O)C(C)(C)C)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 AWTGTSYTZIFAQF-UHFFFAOYSA-N 0.000 description 2
- LRFPIHCDDAVNEG-UHFFFAOYSA-N [4-(acetyloxymethyl)-2-[3-[di(propan-2-yl)amino]-1-phenylpropyl]phenyl] benzoate Chemical compound C=1C(COC(C)=O)=CC=C(OC(=O)C=2C=CC=CC=2)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 LRFPIHCDDAVNEG-UHFFFAOYSA-N 0.000 description 2
- DUGOFTADVMDQRI-UHFFFAOYSA-N [4-[tert-butyl(dimethyl)silyl]oxy-3-[3-[di(propan-2-yl)amino]-1-phenylpropyl]phenyl]methyl acetate Chemical compound C=1C(COC(C)=O)=CC=C(O[Si](C)(C)C(C)(C)C)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 DUGOFTADVMDQRI-UHFFFAOYSA-N 0.000 description 2
- VSQHRRCGQPXSBF-UHFFFAOYSA-N [4-acetyloxy-3-[3-[di(propan-2-yl)amino]-1-phenylpropyl]phenyl]methyl 2,2-dimethylpropanoate Chemical compound C=1C(COC(=O)C(C)(C)C)=CC=C(OC(C)=O)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 VSQHRRCGQPXSBF-UHFFFAOYSA-N 0.000 description 2
- OOHFNCCDLJCABN-UHFFFAOYSA-N [4-benzoyloxy-3-[3-[di(propan-2-yl)amino]-1-phenylpropyl]phenyl]methyl benzoate Chemical compound C=1C(COC(=O)C=2C=CC=CC=2)=CC=C(OC(=O)C=2C=CC=CC=2)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 OOHFNCCDLJCABN-UHFFFAOYSA-N 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 150000001350 alkyl halides Chemical class 0.000 description 2
- 150000008051 alkyl sulfates Chemical class 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000001078 anti-cholinergic effect Effects 0.000 description 2
- HXTPXAYVOHTNNY-UHFFFAOYSA-N bis[2-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl] butanedioate Chemical compound C=1C(CO)=CC=C(OC(=O)CCC(=O)OC=2C(=CC(CO)=CC=2)C(CCN(C(C)C)C(C)C)C=2C=CC=CC=2)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 HXTPXAYVOHTNNY-UHFFFAOYSA-N 0.000 description 2
- YJNYGULGSGQMLB-UHFFFAOYSA-N bis[2-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl] propanedioate Chemical compound C=1C(CO)=CC=C(OC(=O)CC(=O)OC=2C(=CC(CO)=CC=2)C(CCN(C(C)C)C(C)C)C=2C=CC=CC=2)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 YJNYGULGSGQMLB-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 125000004799 bromophenyl group Chemical group 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- YMWUJEATGCHHMB-DICFDUPASA-N dichloromethane-d2 Chemical compound [2H]C([2H])(Cl)Cl YMWUJEATGCHHMB-DICFDUPASA-N 0.000 description 2
- 125000005442 diisocyanate group Chemical group 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- VEXUDELPDQBTKZ-UHFFFAOYSA-N ethyl 2-[[2-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenoxy]carbonylamino]acetate;hydrochloride Chemical compound Cl.CCOC(=O)CNC(=O)OC1=CC=C(CO)C=C1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 VEXUDELPDQBTKZ-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- JBFYUZGYRGXSFL-UHFFFAOYSA-N imidazolide Chemical compound C1=C[N-]C=N1 JBFYUZGYRGXSFL-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- SXFFQILYKHDSIZ-UHFFFAOYSA-N methyl 3-(5-bromo-2-phenylmethoxyphenyl)-3-phenylpropanoate Chemical compound C=1C(Br)=CC=C(OCC=2C=CC=CC=2)C=1C(CC(=O)OC)C1=CC=CC=C1 SXFFQILYKHDSIZ-UHFFFAOYSA-N 0.000 description 2
- ZREVPFANJBZHEU-UHFFFAOYSA-N methyl 3-bromo-4-methoxybenzoate Chemical compound COC(=O)C1=CC=C(OC)C(Br)=C1 ZREVPFANJBZHEU-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 230000003551 muscarinic effect Effects 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- LQVYKEXVMZXOAH-UHFFFAOYSA-N oct-4-enedioic acid Chemical compound OC(=O)CCC=CCCC(O)=O LQVYKEXVMZXOAH-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 125000005359 phenoxyalkyl group Chemical group 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 238000001525 receptor binding assay Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000006798 ring closing metathesis reaction Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 238000000825 ultraviolet detection Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical class CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 1
- ZLFOBEQQEYLXII-CDPFCLIVSA-N (2S,3R,4S,5R,6R)-3,4,5-triacetyl-6-[[4-benzoyloxy-3-[3-[di(propan-2-yl)amino]-1-phenylpropyl]phenyl]methoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound C(C)(C)N(CCC(C1=CC=CC=C1)C1=C(C=CC(=C1)CO[C@H]1[C@](O)([C@@](O)([C@](O)([C@H](O1)C(=O)O)C(C)=O)C(C)=O)C(C)=O)OC(C1=CC=CC=C1)=O)C(C)C ZLFOBEQQEYLXII-CDPFCLIVSA-N 0.000 description 1
- FFBSRTJMTVOAEC-HXUWFJFHSA-N (2r)-2-(5-bromo-2-phenylmethoxyphenyl)-3-phenylpropanoic acid Chemical compound C([C@@H](C(=O)O)C=1C(=CC=C(Br)C=1)OCC=1C=CC=CC=1)C1=CC=CC=C1 FFBSRTJMTVOAEC-HXUWFJFHSA-N 0.000 description 1
- IYZXUVWSCZOBJG-FZNBYNMYSA-N (4r)-3-[(e)-3-(5-bromo-2-phenylmethoxyphenyl)prop-2-enoyl]-4-phenyl-1,3-oxazolidin-2-one Chemical compound C([C@H]1C=2C=CC=CC=2)OC(=O)N1C(=O)/C=C/C1=CC(Br)=CC=C1OCC1=CC=CC=C1 IYZXUVWSCZOBJG-FZNBYNMYSA-N 0.000 description 1
- IYZXUVWSCZOBJG-QFIPXVFZSA-N (4r)-3-[3-(5-bromo-2-phenylmethoxyphenyl)prop-2-enoyl]-4-phenyl-1,3-oxazolidin-2-one Chemical compound C([C@H]1C=2C=CC=CC=2)OC(=O)N1C(=O)C=CC1=CC(Br)=CC=C1OCC1=CC=CC=C1 IYZXUVWSCZOBJG-QFIPXVFZSA-N 0.000 description 1
- WOGITNXCNOTRLK-VOTSOKGWSA-N (e)-3-phenylprop-2-enoyl chloride Chemical compound ClC(=O)\C=C\C1=CC=CC=C1 WOGITNXCNOTRLK-VOTSOKGWSA-N 0.000 description 1
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- CSWXERYZXMPGFS-UHFFFAOYSA-N 2-[3-[3-[di(propan-2-yl)amino]phenyl]propyl]-4-(hydroxymethyl)phenol Chemical compound CC(C)N(C(C)C)C1=CC=CC(CCCC=2C(=CC=C(CO)C=2)O)=C1 CSWXERYZXMPGFS-UHFFFAOYSA-N 0.000 description 1
- IEKNHKFBHBENMC-UHFFFAOYSA-N 2-[3-[di(propan-2-yl)amino]-1-phenylpropyl]phenol Chemical class C=1C=CC=C(O)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 IEKNHKFBHBENMC-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical class Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 125000003541 2-chlorobenzoyl group Chemical group ClC1=C(C(=O)*)C=CC=C1 0.000 description 1
- 125000006282 2-chlorobenzyl group Chemical group [H]C1=C([H])C(Cl)=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000002927 2-methoxybenzyl group Chemical group [H]C1=C([H])C([H])=C(C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 description 1
- 125000006179 2-methyl benzyl group Chemical group [H]C1=C([H])C(=C(C([H])=C1[H])C([H])([H])*)C([H])([H])[H] 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- DOZZSWAOPDYVLH-UHFFFAOYSA-N 2-phenylpropanamide Chemical compound NC(=O)C(C)C1=CC=CC=C1 DOZZSWAOPDYVLH-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- UCYJWCSOSZIQLQ-UHFFFAOYSA-N 3-(5-bromo-2-phenylmethoxyphenyl)-3-phenyl-n,n-di(propan-2-yl)propan-1-amine Chemical compound C=1C(Br)=CC=C(OCC=2C=CC=CC=2)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 UCYJWCSOSZIQLQ-UHFFFAOYSA-N 0.000 description 1
- JMUYVFMRSLESOK-UHFFFAOYSA-N 3-(5-bromo-2-phenylmethoxyphenyl)-3-phenyl-n,n-di(propan-2-yl)propanamide Chemical compound C=1C(Br)=CC=C(OCC=2C=CC=CC=2)C=1C(CC(=O)N(C(C)C)C(C)C)C1=CC=CC=C1 JMUYVFMRSLESOK-UHFFFAOYSA-N 0.000 description 1
- KJWIVHKZEWPBJI-UHFFFAOYSA-N 3-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-phenylmethoxybenzoic acid Chemical compound C=1C(C(O)=O)=CC=C(OCC=2C=CC=CC=2)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 KJWIVHKZEWPBJI-UHFFFAOYSA-N 0.000 description 1
- MFEFEHDEYZENLP-UHFFFAOYSA-N 3-phenyl-n,n-di(propan-2-yl)-3-[2-trimethylsilyloxy-5-(trimethylsilyloxymethyl)phenyl]propan-1-amine Chemical compound C=1C(CO[Si](C)(C)C)=CC=C(O[Si](C)(C)C)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 MFEFEHDEYZENLP-UHFFFAOYSA-N 0.000 description 1
- 125000001999 4-Methoxybenzoyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C(*)=O 0.000 description 1
- QYSOLIUQGINJSE-UHFFFAOYSA-N 4-[[tert-butyl(dimethyl)silyl]oxymethyl]-2-[3-[di(propan-2-yl)amino]-1-phenylpropyl]phenol Chemical compound C=1C(CO[Si](C)(C)C(C)(C)C)=CC=C(O)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 QYSOLIUQGINJSE-UHFFFAOYSA-N 0.000 description 1
- FJKZESVMNVIVCX-UHFFFAOYSA-N 4-[[tert-butyl(diphenyl)silyl]oxymethyl]-2-[3-[di(propan-2-yl)amino]-1-phenylpropyl]phenol Chemical compound C=1C(CO[Si](C=2C=CC=CC=2)(C=2C=CC=CC=2)C(C)(C)C)=CC=C(O)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 FJKZESVMNVIVCX-UHFFFAOYSA-N 0.000 description 1
- JVPZKVIYSYEUID-UHFFFAOYSA-N 4-[tert-butyl(dimethyl)silyl]oxy-3-[3-[di(propan-2-yl)amino]-1-phenylpropyl]phenol Chemical compound C=1C(O)=CC=C(O[Si](C)(C)C(C)(C)C)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 JVPZKVIYSYEUID-UHFFFAOYSA-N 0.000 description 1
- GZFGOTFRPZRKDS-UHFFFAOYSA-N 4-bromophenol Chemical compound OC1=CC=C(Br)C=C1 GZFGOTFRPZRKDS-UHFFFAOYSA-N 0.000 description 1
- 125000000242 4-chlorobenzoyl group Chemical group ClC1=CC=C(C(=O)*)C=C1 0.000 description 1
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 description 1
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000006181 4-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])C([H])([H])* 0.000 description 1
- KFKFQGCDFMGUCH-UHFFFAOYSA-N 6-bromo-4-phenyl-3,4-dihydrochromen-2-one Chemical compound C12=CC(Br)=CC=C2OC(=O)CC1C1=CC=CC=C1 KFKFQGCDFMGUCH-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- BNPXBJDAADFHNO-FTBISJDPSA-N C(C(C)(C)C)(=O)Cl.C(C1=CC=CC=C1)OC1=C(C=C(C=C1)Br)C=CC(=O)N1C(OC[C@H]1C1=CC=CC=C1)=O Chemical compound C(C(C)(C)C)(=O)Cl.C(C1=CC=CC=C1)OC1=C(C=C(C=C1)Br)C=CC(=O)N1C(OC[C@H]1C1=CC=CC=C1)=O BNPXBJDAADFHNO-FTBISJDPSA-N 0.000 description 1
- FSLBEOWZEOFHBV-WDTRHKCHSA-N C(C)(C)N(CCC(C1=CC=CC=C1)C1=C(C=CC(=C1)CO)OC(C(C)(C)C)=O)C(C)C.C(C)(C)N(CC[C@H](C1=CC=CC=C1)C1=C(C=CC(=C1)CO)OC(C(C)C)=O)C(C)C Chemical compound C(C)(C)N(CCC(C1=CC=CC=C1)C1=C(C=CC(=C1)CO)OC(C(C)(C)C)=O)C(C)C.C(C)(C)N(CC[C@H](C1=CC=CC=C1)C1=C(C=CC(=C1)CO)OC(C(C)C)=O)C(C)C FSLBEOWZEOFHBV-WDTRHKCHSA-N 0.000 description 1
- OPCAIUJQNLMJRA-UHFFFAOYSA-N C(C)(C)N(CCC(C1=CC=CC=C1)C=1C=C(C=CC=1CO[Si](C)(C)C)CO)C(C)C Chemical compound C(C)(C)N(CCC(C1=CC=CC=C1)C=1C=C(C=CC=1CO[Si](C)(C)C)CO)C(C)C OPCAIUJQNLMJRA-UHFFFAOYSA-N 0.000 description 1
- UFOLISBEORYILG-UHFFFAOYSA-N C(C1=CC=CC=C1)OC1=C(C=C(C=C1)Br)C(CC(=O)O)C1=CC=CC=C1.C(C1=CC=CC=C1)OC1=C(C=C(C=C1)Br)C(CC(=O)O)C1=CC=CC=C1 Chemical compound C(C1=CC=CC=C1)OC1=C(C=C(C=C1)Br)C(CC(=O)O)C1=CC=CC=C1.C(C1=CC=CC=C1)OC1=C(C=C(C=C1)Br)C(CC(=O)O)C1=CC=CC=C1 UFOLISBEORYILG-UHFFFAOYSA-N 0.000 description 1
- IYZXUVWSCZOBJG-JOCHJYFZSA-N C(C1=CC=CC=C1)OC1=C(C=C(C=C1)Br)C=CC(=O)N1C(OC[C@@H]1C1=CC=CC=C1)=O Chemical compound C(C1=CC=CC=C1)OC1=C(C=C(C=C1)Br)C=CC(=O)N1C(OC[C@@H]1C1=CC=CC=C1)=O IYZXUVWSCZOBJG-JOCHJYFZSA-N 0.000 description 1
- MLYGTJGOAZMBFB-HXUWFJFHSA-N C(C1=CC=CC=C1)OC1=C(C=C(C=C1)Br)[C@H](C=C)C1=CC=CC=C1 Chemical group C(C1=CC=CC=C1)OC1=C(C=C(C=C1)Br)[C@H](C=C)C1=CC=CC=C1 MLYGTJGOAZMBFB-HXUWFJFHSA-N 0.000 description 1
- LGDNTFOAVLINPV-UHFFFAOYSA-N C(C1=CC=CC=C1)OC1=C(C=O)C=C(C=C1)Br.C(C1=CC=CC=C1)OC1=C(C=C(C=C1)Br)C=CC(=O)O Chemical compound C(C1=CC=CC=C1)OC1=C(C=O)C=C(C=C1)Br.C(C1=CC=CC=C1)OC1=C(C=C(C=C1)Br)C=CC(=O)O LGDNTFOAVLINPV-UHFFFAOYSA-N 0.000 description 1
- YLAQBKNOSDLSGT-UHFFFAOYSA-N C(C1=CC=CC=C1)S(=O)(=O)O.C(C1=CC=CC=C1)OC1=C(C=C(C=C1)Br)C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 Chemical compound C(C1=CC=CC=C1)S(=O)(=O)O.C(C1=CC=CC=C1)OC1=C(C=C(C=C1)Br)C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 YLAQBKNOSDLSGT-UHFFFAOYSA-N 0.000 description 1
- FCSWOBWTQUESFA-UHFFFAOYSA-N CC(C)N(CC(Cc1cc(CO[Si](c2ccccc2)(c2ccccc2)C(C)(C)C)ccc1O[Si](C)(C)C(C)(C)C)c1ccccc1)C(C)C Chemical compound CC(C)N(CC(Cc1cc(CO[Si](c2ccccc2)(c2ccccc2)C(C)(C)C)ccc1O[Si](C)(C)C(C)(C)C)c1ccccc1)C(C)C FCSWOBWTQUESFA-UHFFFAOYSA-N 0.000 description 1
- GDMNEOMAFHTKHF-HXUWFJFHSA-N CC(C)N(CC[C@H](C1=CC=CCC1)c(cc(CO)cc1)c1O)C(C)C Chemical compound CC(C)N(CC[C@H](C1=CC=CCC1)c(cc(CO)cc1)c1O)C(C)C GDMNEOMAFHTKHF-HXUWFJFHSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- MVPRSMZXCVUEDX-UHFFFAOYSA-N Cl.C=1C(COC(=O)C=2C=CC=CC=2)=CC=C(OC(=O)C=2C=CC=CC=2)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 Chemical compound Cl.C=1C(COC(=O)C=2C=CC=CC=2)=CC=C(OC(=O)C=2C=CC=CC=2)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 MVPRSMZXCVUEDX-UHFFFAOYSA-N 0.000 description 1
- SOABFVJWAVWTRY-UHFFFAOYSA-N Cl.C=1C(COS(O)(=O)=O)=CC=C(OC(=O)C=2C=CC=CC=2)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 Chemical compound Cl.C=1C(COS(O)(=O)=O)=CC=C(OC(=O)C=2C=CC=CC=2)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 SOABFVJWAVWTRY-UHFFFAOYSA-N 0.000 description 1
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 1
- DUXZAXCGJSBGDW-HXUWFJFHSA-N Desfesoterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(CO)C=2)O)=CC=CC=C1 DUXZAXCGJSBGDW-HXUWFJFHSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 206010020853 Hypertonic bladder Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229910010082 LiAlH Inorganic materials 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- RJUFJBKOKNCXHH-UHFFFAOYSA-N Methyl propionate Chemical compound CCC(=O)OC RJUFJBKOKNCXHH-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 238000006751 Mitsunobu reaction Methods 0.000 description 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 description 1
- DYUQAZSOFZSPHD-UHFFFAOYSA-N Phenylpropanol Chemical compound CCC(O)C1=CC=CC=C1 DYUQAZSOFZSPHD-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- KGNKBMFLHKBDSX-AREMUKBSSA-N [2-[(1r)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl] benzoate Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(CO)C=2)OC(=O)C=2C=CC=CC=2)=CC=CC=C1 KGNKBMFLHKBDSX-AREMUKBSSA-N 0.000 description 1
- XRDRVDDMLLSKLV-UHFFFAOYSA-N [2-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(ethoxymethyl)phenyl] acetate Chemical compound CCOCC1=CC=C(OC(C)=O)C(C(CCN(C(C)C)C(C)C)C=2C=CC=CC=2)=C1 XRDRVDDMLLSKLV-UHFFFAOYSA-N 0.000 description 1
- UUQZJCVJLILIBJ-UHFFFAOYSA-N [2-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl] 2,2-dimethylpropanoate Chemical compound C=1C(CO)=CC=C(OC(=O)C(C)(C)C)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 UUQZJCVJLILIBJ-UHFFFAOYSA-N 0.000 description 1
- QUNXUCGMFQRLGW-UHFFFAOYSA-N [2-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl] 4-methoxybenzoate Chemical compound C1=CC(OC)=CC=C1C(=O)OC1=CC=C(CO)C=C1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 QUNXUCGMFQRLGW-UHFFFAOYSA-N 0.000 description 1
- COPIGDPPLIVQTA-UHFFFAOYSA-N [2-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl] acetate Chemical compound C=1C(CO)=CC=C(OC(C)=O)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 COPIGDPPLIVQTA-UHFFFAOYSA-N 0.000 description 1
- COQSZSOHODRSCC-UHFFFAOYSA-N [2-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl] cyclohexanecarboxylate Chemical compound C=1C(CO)=CC=C(OC(=O)C2CCCCC2)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 COQSZSOHODRSCC-UHFFFAOYSA-N 0.000 description 1
- UVWOPVDJJLVMNA-UHFFFAOYSA-N [2-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl] ethyl carbonate Chemical compound CCOC(=O)OC1=CC=C(CO)C=C1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 UVWOPVDJJLVMNA-UHFFFAOYSA-N 0.000 description 1
- PYJGAVVIWWRPCC-UHFFFAOYSA-N [2-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl] formate Chemical compound C=1C(CO)=CC=C(OC=O)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 PYJGAVVIWWRPCC-UHFFFAOYSA-N 0.000 description 1
- BVEKXWODCHFMIT-UHFFFAOYSA-N [2-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl] n,n-dimethylcarbamate Chemical compound C=1C(CO)=CC=C(OC(=O)N(C)C)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 BVEKXWODCHFMIT-UHFFFAOYSA-N 0.000 description 1
- QSCNZVWGTYTPBU-UHFFFAOYSA-N [2-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl] phenyl carbonate Chemical compound C=1C(CO)=CC=C(OC(=O)OC=2C=CC=CC=2)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 QSCNZVWGTYTPBU-UHFFFAOYSA-N 0.000 description 1
- FLFRDVLCYBODJR-UHFFFAOYSA-N [2-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(phenoxycarbonyloxymethyl)phenyl] phenyl carbonate Chemical compound C=1C(COC(=O)OC=2C=CC=CC=2)=CC=C(OC(=O)OC=2C=CC=CC=2)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 FLFRDVLCYBODJR-UHFFFAOYSA-N 0.000 description 1
- BEDSMQJGXDJAFB-UHFFFAOYSA-N [2-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(sulfooxymethyl)phenyl] benzoate Chemical compound C=1C(COS(O)(=O)=O)=CC=C(OC(=O)C=2C=CC=CC=2)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 BEDSMQJGXDJAFB-UHFFFAOYSA-N 0.000 description 1
- JFHVYJSOKBSYRX-UHFFFAOYSA-N [3-(5-bromo-2-phenylmethoxyphenyl)-3-phenylpropyl] 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCCC(C=1C(=CC=C(Br)C=1)OCC=1C=CC=CC=1)C1=CC=CC=C1 JFHVYJSOKBSYRX-UHFFFAOYSA-N 0.000 description 1
- GVKBRMPULOEHLO-HHHXNRCGSA-N [3-[(1r)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-phenylmethoxyphenyl]methanol Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(CO)C=2)OCC=2C=CC=CC=2)=CC=CC=C1 GVKBRMPULOEHLO-HHHXNRCGSA-N 0.000 description 1
- ONAYLBCJKSLQDV-UHFFFAOYSA-N [3-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-hydroxyphenyl]methyl 2,2-dimethylpropanoate Chemical compound C=1C(COC(=O)C(C)(C)C)=CC=C(O)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 ONAYLBCJKSLQDV-UHFFFAOYSA-N 0.000 description 1
- KOULVVBWHDZSHA-UHFFFAOYSA-N [3-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-hydroxyphenyl]methyl benzoate Chemical compound C=1C(COC(=O)C=2C=CC=CC=2)=CC=C(O)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 KOULVVBWHDZSHA-UHFFFAOYSA-N 0.000 description 1
- XFTUDCJRXMYXDL-UHFFFAOYSA-N [3-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-phenylmethoxyphenyl]methyl 2-methylpropanoate Chemical compound C=1C(COC(=O)C(C)C)=CC=C(OCC=2C=CC=CC=2)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 XFTUDCJRXMYXDL-UHFFFAOYSA-N 0.000 description 1
- INCOYGJLNTWJRS-UHFFFAOYSA-N [3-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-propanoyloxyphenyl]methyl propanoate Chemical compound CCC(=O)OCC1=CC=C(OC(=O)CC)C(C(CCN(C(C)C)C(C)C)C=2C=CC=CC=2)=C1 INCOYGJLNTWJRS-UHFFFAOYSA-N 0.000 description 1
- SEHCTGCUIKWNLH-UHFFFAOYSA-N [3-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-trimethylsilyloxyphenyl]methanol Chemical compound C=1C(CO)=CC=C(O[Si](C)(C)C)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 SEHCTGCUIKWNLH-UHFFFAOYSA-N 0.000 description 1
- VEVRXYWNXTUOPG-UHFFFAOYSA-N [4-(2,2-dimethylpropanoyloxy)-3-[3-[di(propan-2-yl)amino]-1-phenylpropyl]phenyl]methyl 2,2-dimethylpropanoate Chemical compound C=1C(COC(=O)C(C)(C)C)=CC=C(OC(=O)C(C)(C)C)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 VEVRXYWNXTUOPG-UHFFFAOYSA-N 0.000 description 1
- LRFPIHCDDAVNEG-MUUNZHRXSA-N [4-(acetyloxymethyl)-2-[(1r)-3-[di(propan-2-yl)amino]-1-phenylpropyl]phenyl] benzoate Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(COC(C)=O)C=2)OC(=O)C=2C=CC=CC=2)=CC=CC=C1 LRFPIHCDDAVNEG-MUUNZHRXSA-N 0.000 description 1
- JZGVMECQBSXCTG-UHFFFAOYSA-N [4-[[tert-butyl(diphenyl)silyl]oxymethyl]-2-[3-[di(propan-2-yl)amino]-1-phenylpropyl]phenyl] acetate Chemical compound C=1C(CO[Si](C=2C=CC=CC=2)(C=2C=CC=CC=2)C(C)(C)C)=CC=C(OC(C)=O)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 JZGVMECQBSXCTG-UHFFFAOYSA-N 0.000 description 1
- FCFZATJYNWJMCC-UHFFFAOYSA-N [4-[tert-butyl(dimethyl)silyl]oxy-2-[3-[di(propan-2-yl)amino]-1-phenylpropyl]phenyl] acetate Chemical compound C=1C(O[Si](C)(C)C(C)(C)C)=CC=C(OC(C)=O)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 FCFZATJYNWJMCC-UHFFFAOYSA-N 0.000 description 1
- SGRHEKPPVGNDJJ-UHFFFAOYSA-N [4-[tert-butyl(dimethyl)silyl]oxy-3-[3-[di(propan-2-yl)amino]-1-phenylpropyl]phenyl]methanol Chemical compound C=1C(CO)=CC=C(O[Si](C)(C)C(C)(C)C)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 SGRHEKPPVGNDJJ-UHFFFAOYSA-N 0.000 description 1
- WSFRISHKDDRIBV-UHFFFAOYSA-N [4-acetyloxy-3-[3-[di(propan-2-yl)amino]-1-phenylpropyl]phenyl]methyl acetate Chemical compound C=1C(COC(C)=O)=CC=C(OC(C)=O)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 WSFRISHKDDRIBV-UHFFFAOYSA-N 0.000 description 1
- OOHFNCCDLJCABN-JGCGQSQUSA-N [4-benzoyloxy-3-[(1r)-3-[di(propan-2-yl)amino]-1-phenylpropyl]phenyl]methyl benzoate Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(COC(=O)C=3C=CC=CC=3)C=2)OC(=O)C=2C=CC=CC=2)=CC=CC=C1 OOHFNCCDLJCABN-JGCGQSQUSA-N 0.000 description 1
- FEZQSTUBPKSSOW-XFBYMFPWSA-L [Cu](Cl)Cl.C(C1=CC=CC=C1)OC1=C(C=C(C=C1)Br)[C@@H](CC(=O)N1C(OC[C@H]1C1=CC=CC=C1)=O)C1=CC=CC=C1 Chemical compound [Cu](Cl)Cl.C(C1=CC=CC=C1)OC1=C(C=C(C=C1)Br)[C@@H](CC(=O)N1C(OC[C@H]1C1=CC=CC=C1)=O)C1=CC=CC=C1 FEZQSTUBPKSSOW-XFBYMFPWSA-L 0.000 description 1
- ADSXDBCZNVXTRD-UHFFFAOYSA-N [Mg]C1=CC=CC=C1 Chemical compound [Mg]C1=CC=CC=C1 ADSXDBCZNVXTRD-UHFFFAOYSA-N 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- ORWKVZNEPHTCQE-UHFFFAOYSA-N acetic formic anhydride Chemical compound CC(=O)OC=O ORWKVZNEPHTCQE-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000006480 benzoylation reaction Methods 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- GCTPMLUUWLLESL-UHFFFAOYSA-N benzyl prop-2-enoate Chemical class C=CC(=O)OCC1=CC=CC=C1 GCTPMLUUWLLESL-UHFFFAOYSA-N 0.000 description 1
- PNPBGYBHLCEVMK-UHFFFAOYSA-L benzylidene(dichloro)ruthenium;tricyclohexylphosphane Chemical compound Cl[Ru](Cl)=CC1=CC=CC=C1.C1CCCCC1P(C1CCCCC1)C1CCCCC1.C1CCCCC1P(C1CCCCC1)C1CCCCC1 PNPBGYBHLCEVMK-UHFFFAOYSA-L 0.000 description 1
- PNPBGYBHLCEVMK-UHFFFAOYSA-N benzylidene(dichloro)ruthenium;tricyclohexylphosphanium Chemical compound Cl[Ru](Cl)=CC1=CC=CC=C1.C1CCCCC1[PH+](C1CCCCC1)C1CCCCC1.C1CCCCC1[PH+](C1CCCCC1)C1CCCCC1 PNPBGYBHLCEVMK-UHFFFAOYSA-N 0.000 description 1
- QUKGYYKBILRGFE-UHFFFAOYSA-N benzyloxyacetoaldehyde Natural products CC(=O)OCC1=CC=CC=C1 QUKGYYKBILRGFE-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- SVRGEWPWLONPFO-UHFFFAOYSA-N bis[2-[3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl] pentanedioate Chemical compound C=1C(CO)=CC=C(OC(=O)CCCC(=O)OC=2C(=CC(CO)=CC=2)C(CCN(C(C)C)C(C)C)C=2C=CC=CC=2)C=1C(CCN(C(C)C)C(C)C)C1=CC=CC=C1 SVRGEWPWLONPFO-UHFFFAOYSA-N 0.000 description 1
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000000451 chemical ionisation Methods 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- CZKMPDNXOGQMFW-UHFFFAOYSA-N chloro(triethyl)germane Chemical compound CC[Ge](Cl)(CC)CC CZKMPDNXOGQMFW-UHFFFAOYSA-N 0.000 description 1
- HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 description 1
- XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000002920 convulsive effect Effects 0.000 description 1
- NKNDPYCGAZPOFS-UHFFFAOYSA-M copper(i) bromide Chemical compound Br[Cu] NKNDPYCGAZPOFS-UHFFFAOYSA-M 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000006392 deoxygenation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000005828 desilylation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 108700003601 dimethylglycine Proteins 0.000 description 1
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- BLCTWBJQROOONQ-UHFFFAOYSA-N ethenyl prop-2-enoate Chemical compound C=COC(=O)C=C BLCTWBJQROOONQ-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- DCCSDBARQIPTGU-HSZRJFAPSA-N fesoterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(CO)C=2)OC(=O)C(C)C)=CC=CC=C1 DCCSDBARQIPTGU-HSZRJFAPSA-N 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 125000002367 glucuronosyl group Chemical group 0.000 description 1
- BCDGQXUMWHRQCB-UHFFFAOYSA-N glycine methyl ketone Natural products CC(=O)CN BCDGQXUMWHRQCB-UHFFFAOYSA-N 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000011984 grubbs catalyst Substances 0.000 description 1
- 238000011597 hartley guinea pig Methods 0.000 description 1
- UQEAIHBTYFGYIE-UHFFFAOYSA-N hexamethyldisiloxane Chemical class C[Si](C)(C)O[Si](C)(C)C UQEAIHBTYFGYIE-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 150000002440 hydroxy compounds Chemical class 0.000 description 1
- 230000000640 hydroxylating effect Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- AUONNNVJUCSETH-UHFFFAOYSA-N icosanoyl icosanoate Chemical compound CCCCCCCCCCCCCCCCCCCC(=O)OC(=O)CCCCCCCCCCCCCCCCCCC AUONNNVJUCSETH-UHFFFAOYSA-N 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002485 inorganic esters Chemical class 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 229950003188 isovaleryl diethylamide Drugs 0.000 description 1
- 150000002561 ketenes Chemical class 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 125000001998 leucyl group Chemical group 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 1
- 229960002329 methacholine Drugs 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 239000002032 methanolic fraction Substances 0.000 description 1
- 125000002073 methionyl group Chemical group 0.000 description 1
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 239000000472 muscarinic agonist Substances 0.000 description 1
- 229940078490 n,n-dimethylglycine Drugs 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 208000020629 overactive bladder Diseases 0.000 description 1
- 125000003232 p-nitrobenzoyl group Chemical group [N+](=O)([O-])C1=CC=C(C(=O)*)C=C1 0.000 description 1
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 150000002972 pentoses Chemical class 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 125000000405 phenylalanyl group Chemical group 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- ANRQGKOBLBYXFM-UHFFFAOYSA-M phenylmagnesium bromide Chemical compound Br[Mg]C1=CC=CC=C1 ANRQGKOBLBYXFM-UHFFFAOYSA-M 0.000 description 1
- 229950009195 phenylpropanol Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-M pivalate Chemical compound CC(C)(C)C([O-])=O IUGYQRQAERSCNH-UHFFFAOYSA-M 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- CHWRSCGUEQEHOH-UHFFFAOYSA-N potassium oxide Chemical compound [O-2].[K+].[K+] CHWRSCGUEQEHOH-UHFFFAOYSA-N 0.000 description 1
- 229910001950 potassium oxide Inorganic materials 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 229960003857 proglumide Drugs 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- USYCSHPNZNNCCU-UHFFFAOYSA-N prop-1-en-2-yl prop-2-enoate Chemical compound CC(=C)OC(=O)C=C USYCSHPNZNNCCU-UHFFFAOYSA-N 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000012495 reaction gas Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- CQRYARSYNCAZFO-UHFFFAOYSA-N salicyl alcohol Chemical compound OCC1=CC=CC=C1O CQRYARSYNCAZFO-UHFFFAOYSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 125000002072 seryl group Chemical group 0.000 description 1
- 238000006884 silylation reaction Methods 0.000 description 1
- 231100000245 skin permeability Toxicity 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 230000003033 spasmogenic effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000001239 threonyl group Chemical group 0.000 description 1
- APEJMQOBVMLION-VOTSOKGWSA-N trans-cinnamamide Chemical compound NC(=O)\C=C\C1=CC=CC=C1 APEJMQOBVMLION-VOTSOKGWSA-N 0.000 description 1
- 239000005051 trimethylchlorosilane Substances 0.000 description 1
- 125000002114 valyl group Chemical group 0.000 description 1
- KOZCZZVUFDCZGG-UHFFFAOYSA-N vinyl benzoate Chemical compound C=COC(=O)C1=CC=CC=C1 KOZCZZVUFDCZGG-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Images
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98108608A EP0957073A1 (en) | 1998-05-12 | 1998-05-12 | Novel derivatives of 3,3-diphenylpropylamines |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000548284A Division JP3929702B2 (ja) | 1998-05-12 | 1999-05-11 | ３，３−ジフェニルプロピルアミンの新規な誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007084552A JP2007084552A (ja) | 2007-04-05 |
| JP2007084552A5 true JP2007084552A5 (cg-RX-API-DMAC10.html) | 2007-05-24 |
| JP4658895B2 JP4658895B2 (ja) | 2011-03-23 |
Family
ID=8231918
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000548284A Expired - Lifetime JP3929702B2 (ja) | 1998-05-12 | 1999-05-11 | ３，３−ジフェニルプロピルアミンの新規な誘導体 |
| JP2006283861A Expired - Lifetime JP4658895B2 (ja) | 1998-05-12 | 2006-10-18 | ３，３−ジフェニルプロピルアミンの新規な誘導体 |
| JP2007039857A Expired - Lifetime JP4833884B2 (ja) | 1998-05-12 | 2007-02-20 | ３，３−ジフェニルプロピルアミンの新規な誘導体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000548284A Expired - Lifetime JP3929702B2 (ja) | 1998-05-12 | 1999-05-11 | ３，３−ジフェニルプロピルアミンの新規な誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007039857A Expired - Lifetime JP4833884B2 (ja) | 1998-05-12 | 2007-02-20 | ３，３−ジフェニルプロピルアミンの新規な誘導体 |
Country Status (32)
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0957073A1 (en) | 1998-05-12 | 1999-11-17 | Schwarz Pharma Ag | Novel derivatives of 3,3-diphenylpropylamines |
| DE19955190A1 (de) * | 1999-11-16 | 2001-06-21 | Sanol Arznei Schwarz Gmbh | Stabile Salze neuartiger Derivate von 3,3-Diphenylpropylaminen |
| SE9904850D0 (sv) * | 1999-12-30 | 1999-12-30 | Pharmacia & Upjohn Ab | Novel process and intermediates |
| DE10028443C1 (de) * | 2000-06-14 | 2002-05-29 | Sanol Arznei Schwarz Gmbh | Verfahren zur Herstellung von 3,3-Diarylpropylaminen, (R,S)- und (R)-4-Phenyl-2-chromanon-6-carbonsäure sowie (R)-4-Phenyl-2-chromanon-carbonsäure-cinchonidinsalz und deren Verwendung zur Herstellung eines rechtsdrehenden Hydroxybenzylalkohols und von pharmazeutischen Zusammensetzungen |
| DE10033016A1 (de) | 2000-07-07 | 2002-01-24 | Sanol Arznei Schwarz Gmbh | Verfahren zur Herstellung von 3,3-Diarylpropylaminen |
| EP1424079A1 (en) * | 2002-11-27 | 2004-06-02 | Boehringer Ingelheim International GmbH | Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine |
| DE10315917A1 (de) * | 2003-04-08 | 2004-11-18 | Schwarz Pharma Ag | Hochreine Basen von 3,3-Diphenylpropylaminmonoestern |
| DE10315878B4 (de) * | 2003-04-08 | 2009-06-04 | Schwarz Pharma Ag | Vorrichtung zur transdermalen Verabreichung von Fesoterodin und Verwendung |
| WO2004091597A2 (en) * | 2003-04-15 | 2004-10-28 | Pharmacia & Upjohn Company Llc | Method of treating irritable bowel syndrome (ibs) |
| BRPI0409653A (pt) * | 2003-04-25 | 2006-04-25 | Pharmacia & Upjohn Co Llc | 3,3-difenilpropilaminas (tolterodina) substituìdas com halogênio com atividade antimuscarìnica |
| CA2522888C (en) | 2003-05-23 | 2012-07-17 | Bridge Pharma, Inc. | Smooth muscle spasmolytic agents |
| WO2005012227A2 (en) * | 2003-08-05 | 2005-02-10 | Ranbaxy Laboratories Limited | Process for preparation of 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethyl-phenol, a metabolite of tolterodine |
| WO2007039918A1 (en) * | 2005-10-06 | 2007-04-12 | Natco Pharma Limited | Novel process for the preparation of tolterodine |
| EP1965863A2 (en) * | 2005-12-20 | 2008-09-10 | Pfizer Products Inc. | Pharmaceutical combination for the treatment of luts comprising a pde5 inhibitor and a muscarinic antagonist |
| US8119667B2 (en) * | 2005-12-29 | 2012-02-21 | Schering-Plough Animal Health Corporation | Carbonates of fenicol antibiotics |
| ATE480531T1 (de) * | 2006-05-24 | 2010-09-15 | Pfizer Ltd | Verfahren zur herstellung von benzopyran-2- olderivaten |
| JP5257353B2 (ja) * | 2006-05-31 | 2013-08-07 | シュウォーツ ファーマ リミテッド | 置換ヒドロキシメチルフェノールの新規な合成 |
| EP1862449A1 (en) * | 2006-05-31 | 2007-12-05 | Schwarz Pharma Ltd. | A shortened synthesis of substituted hydroxymethyl phenols |
| IES20060424A2 (en) | 2006-06-08 | 2007-10-31 | Schwarz Pharma Ltd | Accelerated synthesis of (3-Diisopropylamino-1-phenylpropyl)-4-(hydroxymethyl)phenol and its phenolic monoesters |
| PL2029134T3 (pl) * | 2006-06-09 | 2011-12-30 | Ucb Pharma Gmbh | Stabilizowane kompozycje farmaceutyczne zawierające fezoterodynę |
| US7807715B2 (en) | 2006-06-09 | 2010-10-05 | Ucb Pharma Gmbh | Pharmaceutical compositions comprising fesoterodine |
| EP2004592B1 (en) * | 2006-06-09 | 2010-08-11 | Schwarz Pharma Ltd. | Synthesis of phenolic esters of hydroxymethyl phenols |
| KR101488740B1 (ko) * | 2006-06-12 | 2015-02-03 | 유씨비 파마 게엠베하 | 새로운 키랄 중간체, 그 키랄 중간체의 제조방법 및 톨테로딘, 페소테로딘 또는 그 활성대사물질의 제조에서 그키랄 중간체의 사용 |
| IES20060435A2 (en) | 2006-06-12 | 2007-12-12 | Schwarz Pharma Ltd | Shortened synthesis using paraformaldehyde or trioxane |
| CZ2006506A3 (cs) * | 2006-08-09 | 2007-10-03 | Zentiva, A. S. | Farmaceutická kompozice s obsahem tolterodinu |
| BRPI0718144B1 (pt) * | 2006-11-17 | 2017-04-04 | Asahi Kasei Chemicals Corp | processo para produzir um isocianato, e, policarbamato de arila |
| TW200844080A (en) | 2007-01-11 | 2008-11-16 | Asahi Kasei Chemicals Corp | Process for producing isocyanate |
| US20090005309A1 (en) * | 2007-05-18 | 2009-01-01 | Auspex Pharmaceuticals, Inc. | Substituted piperidines |
| WO2009006413A1 (en) * | 2007-06-30 | 2009-01-08 | Auspex Pharmaceuticals, Inc. | Substituted pyrrolidines |
| US20090062385A1 (en) * | 2007-08-29 | 2009-03-05 | Protia, Llc | Deuterium-enriched fesoterodine |
| US20090062398A1 (en) * | 2007-08-29 | 2009-03-05 | Protia, Llc | Deuterium-enriched tolterodine |
| WO2009037569A2 (en) * | 2007-09-21 | 2009-03-26 | Actavis Group Ptc Ehf | An improved process for the preparation of fesoterodine |
| US20100297241A1 (en) * | 2007-10-01 | 2010-11-25 | Actavis Group Ptc Ehf | Amorphous Fesoterodine Fumarate |
| AR070950A1 (es) * | 2007-11-01 | 2010-05-19 | Acucela Inc | Compuestos derivados de amina, composiciones farmaceuticas de ellos, compuestos inhibidores de produccion de 11-cis-retinol y metodos para tratar enfermedades y trastornos oftalmicos |
| US20110086103A1 (en) * | 2008-04-04 | 2011-04-14 | Actavis Group Ptc Ehf | Novel mandelate salt of fesoterodine |
| KR101363232B1 (ko) | 2008-05-15 | 2014-02-12 | 아사히 가세이 케미칼즈 가부시키가이샤 | 탄산디아릴을 이용하는 이소시아네이트의 제조 방법 |
| BRPI0822694B1 (pt) | 2008-05-15 | 2018-11-27 | Asahi Kasei Chemicals Corp | processo para produzir um isocianato |
| EP2323967A2 (en) * | 2008-07-21 | 2011-05-25 | Actavis Group PTC EHF | Fesoterodine comprising a reduced amount of dehydroxyfesoterodine |
| JP5381086B2 (ja) * | 2008-10-06 | 2014-01-08 | 日本電気株式会社 | 通信システム及び通信制御方法 |
| US9085507B2 (en) | 2009-05-11 | 2015-07-21 | Ratiopharm Gmbh | Desfesoterodine in the form of a tartaric acid salt |
| IT1394219B1 (it) | 2009-05-15 | 2012-06-01 | Chemi Spa | Metodo di preparazione di fesoterodina fumarato di elevata purezza. |
| IT1394217B1 (it) | 2009-05-15 | 2012-06-01 | Chemi Spa | Metodo di preparazione di fesoterodina e/o fesoterodina fumarato. |
| ES2456866T3 (es) | 2009-07-27 | 2014-04-23 | Crystal Pharma, S.A.U. | Procedimiento para la obtención de 3,3-difenilpropilaminas |
| IT1396373B1 (it) * | 2009-10-29 | 2012-11-19 | Dipharma Francis Srl | Procedimento per la preparazione di fesoterodina. |
| EP2316432A1 (de) | 2009-10-30 | 2011-05-04 | ratiopharm GmbH | Zusammensetzung enthaltend Fesoterodin und Ballaststoffe |
| US20110124903A1 (en) * | 2009-11-20 | 2011-05-26 | Actavis Group Ptc Ehf | Solid state forms of fesoterodine intermediates |
| IT1397521B1 (it) | 2009-12-21 | 2013-01-16 | Dipharma Francis Srl | Procedimento per la preparazione di fesoterodina con un basso contenuto di impurezze. |
| EP2364966A1 (en) | 2010-03-09 | 2011-09-14 | LEK Pharmaceuticals d.d. | Process for preparation of 3-(2-hydroxy-5-substituted phenyl)-3-phenylpropylamines, intermediates for making hydroxytolterodine |
| US20130172411A1 (en) | 2010-03-22 | 2013-07-04 | Cadila Healthcare Limited | Stable pharmaceutical compositions comprising fesoterodine |
| ES2604705T3 (es) | 2010-03-31 | 2017-03-08 | Ono Pharmaceutical Co., Ltd. | Agente preventivo y/o remedio para el síndrome mano-pie |
| CA2796877A1 (en) | 2010-04-30 | 2011-11-03 | Merck Sharp & Dohme Corp. | Novel beta 3 adrenergic receptor agonists |
| US20110282094A1 (en) | 2010-05-11 | 2011-11-17 | Intas Pharmaceuticals Limited | Process for preparation of phenolic monoesters of hydroxymethyl phenols |
| IT1401451B1 (it) * | 2010-06-10 | 2013-07-26 | Chemi Spa | Nuovo processo di preparazione di 2-idrossi-4-fenil-3,4-diidro-2h-cromen-6-il-metanolo e (r)-2-[3-(diisopropilammino)-1-fenilpropil]-4-(idrossimetil)fenolo. |
| WO2011158257A1 (en) | 2010-06-18 | 2011-12-22 | Panacea Biotec Ltd | Preparation process of fesoterodine and intermediates |
| US9012678B2 (en) * | 2010-08-25 | 2015-04-21 | Cadila Healthcare Limited | Processes for the preparation of fesoterodine |
| US8653123B2 (en) * | 2010-09-16 | 2014-02-18 | Allergan, Inc. | Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating retinal diseases |
| IT1403094B1 (it) | 2010-12-09 | 2013-10-04 | Dipharma Francis Srl | Procedimento per la preparazione di fesoterodina o un suo sale |
| WO2012098560A2 (en) * | 2011-01-17 | 2012-07-26 | Msn Laboratories Limited | Process for the preparation of muscarinic receptor antagonist |
| TWI590821B (zh) | 2011-01-18 | 2017-07-11 | 輝瑞有限公司 | 固體分子分散液 |
| US9085509B2 (en) | 2011-04-07 | 2015-07-21 | Alembic Pharmaceuticals Limited | Process for preparing fesoterodine |
| EP2508175A1 (en) | 2011-04-08 | 2012-10-10 | LEK Pharmaceuticals d.d. | Pharmaceutical composition comprising fesoterodine or a salt or a solvate thereof |
| EP2508173A1 (en) | 2011-04-08 | 2012-10-10 | LEK Pharmaceuticals d.d. | Stabilized pharmaceutical composition comprising fesoterodine |
| WO2013021343A1 (en) | 2011-08-05 | 2013-02-14 | Ranbaxy Laboratories Limited | Process for the optical resolution of () -3- (2 -benzyloxy- 5 - bromophenyl) - 3 - phenylpropionic |
| WO2013046135A1 (en) | 2011-09-26 | 2013-04-04 | Ranbaxy Laboratories Limited | Process for the preparation of fesoterodine or its salts |
| US20140378699A1 (en) | 2012-01-07 | 2014-12-25 | Alembic Pharmaceuticals Limited | Process for the preparation of fesoterodine |
| CN103304356B (zh) * | 2012-03-12 | 2016-01-20 | 北京乐威泰克医药技术有限公司 | 羟胺的合成方法 |
| US9422228B2 (en) | 2012-05-04 | 2016-08-23 | Crystal Pharma, S.A.U. | Process for the preparation of optically pure fesoterodine derivatives |
| EP2780317A2 (en) | 2012-05-18 | 2014-09-24 | Alembic Pharmaceuticals Limited | The novel reference markers for fesoterodine fumarate |
| EP2760822B1 (en) | 2012-06-14 | 2016-03-23 | ratiopharm GmbH | Desfesoterodine salts |
| ITMI20121232A1 (it) * | 2012-07-16 | 2014-01-17 | Cambrex Profarmaco Milano Srl | Procedimento per la preparazione di 2-(3-n,n-diisopropilamino-1-fenilpropil)-4-idrossimetil-fenolo e suoi derivati |
| CZ2014400A3 (cs) | 2014-06-09 | 2015-12-16 | Zentiva, K.S. | Stabilizovaná formulace fesoterodinu |
| US9751828B2 (en) | 2014-07-30 | 2017-09-05 | Dipharma Francis S.R.L. | Antimuscarinic compound having a low content of impurities |
| TR201721437A2 (tr) | 2017-12-25 | 2019-07-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Fesoterodi̇ni̇n modi̇fi̇ye salim sağlayan formülasyonlari |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE766207C (de) | 1940-07-08 | 1952-12-22 | Ig Farbenindustrie Ag | Verfahren zur Herstellung von basischen Verbindungen der Diarylmethanreihe |
| DE925468C (de) | 1941-08-13 | 1955-03-21 | Hoechst Ag | Verfahren zur Herstellung von ª†, ª†-Diaryl-propyl-aminen |
| GB624117A (en) | 1946-12-07 | 1949-05-27 | Wellcome Found | Improvements in and relating to the preparation of substituted allylamines and propylamines |
| GB627139A (en) | 1947-05-28 | 1949-07-29 | Wellcome Found | Improvements in and relating to the preparation of quaternary ammonium salts of substituted propanolamines, allylamines and propylamines |
| BE497819A (cg-RX-API-DMAC10.html) | 1947-10-28 | |||
| US2567245A (en) * | 1948-05-10 | 1951-09-11 | Schering Corp | Aryl-(2-pyridyl)-amino alkanes and their production |
| US2556636A (en) * | 1948-06-23 | 1951-06-12 | Schering Corp | gamma-substituted propylamine type antihistamines |
| CH287778A (de) | 1948-11-09 | 1952-12-15 | Michael Dr Erlenbach | Verfahren zur Herstellung einer basischen Verbindung. |
| DE830193C (de) | 1948-11-09 | 1952-02-04 | Farbwerke Hoechst Vormals Meis | Verfahren zur Herstellung von basischen Verbindungen |
| GB685696A (en) | 1948-11-23 | 1953-01-07 | Schering Corp | Process for the manufacture of anti-histaminic compounds |
| NL74271C (cg-RX-API-DMAC10.html) | 1949-09-05 | |||
| US2676964A (en) * | 1950-06-07 | 1954-04-27 | Schering Corp | 3-pyridyl propylamine antihistamine substances |
| US3261841A (en) * | 1961-05-03 | 1966-07-19 | Sterling Drug Inc | N-substituted 1,5-iminocycloalkanes and -alkenes |
| US3216841A (en) * | 1962-04-30 | 1965-11-09 | Clevite Corp | Metal slip casting composition |
| DK111894A (cg-RX-API-DMAC10.html) | 1962-11-15 | |||
| GB1025041A (en) | 1964-02-21 | 1966-04-06 | Hoechst Ag | Process for the manufacture of diphenylalkylamines |
| GB1169945A (en) | 1966-08-25 | 1969-11-05 | Geistlich Soehne Ag | Pharmaceutical Compositions containing Diphenylalkyl-amine Derivatives |
| GB1169944A (en) | 1966-08-25 | 1969-11-05 | Geistlich Soehne Ag | Novel 3,3-Diphenylpropylamines and processes for the preparation thereof |
| HU200591B (en) * | 1986-07-11 | 1990-07-28 | Chinoin Gyogyszer Es Vegyeszet | Process for producing new diphenyl propylamine derivatives and pharmaceutical compositions comprising such compounds |
| US5382600A (en) * | 1988-01-22 | 1995-01-17 | Pharmacia Aktiebolag | 3,3-diphenylpropylamines and pharmaceutical compositions thereof |
| SE8800207D0 (sv) | 1988-01-22 | 1988-01-22 | Kabivitrum Ab | Nya aminer, deras anvendning och framstellning |
| US5693144A (en) * | 1990-03-19 | 1997-12-02 | 3D Systems, Inc. | Vibrationally enhanced stereolithographic recoating |
| ES2137261T3 (es) | 1992-05-13 | 1999-12-16 | Alza Corp | Administracion transdermica de oxibutinina. |
| SE9203318D0 (sv) * | 1992-11-06 | 1992-11-06 | Kabi Pharmacia Ab | Novel 3,3-diphenylpropylamines, their use and preparation |
| US6071970A (en) | 1993-02-08 | 2000-06-06 | Nps Pharmaceuticals, Inc. | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases |
| AU7994694A (en) | 1994-10-21 | 1996-05-15 | Leiras Oy | Controlled release oral delivery system containing oxybutynin |
| US6310103B1 (en) | 1996-07-19 | 2001-10-30 | Bridge Pharma, Inc. | S(−)-tolterodine in the treatment of urinary and gastrointestinal disorders |
| ATE252378T1 (de) | 1996-12-12 | 2003-11-15 | Dds Drug Delivery Service Ges | Zubereitung in form eines wahlweise wirkstoffhaltigen matrixmaterial-hilfsstoff compounds |
| KR20000057548A (ko) * | 1996-12-13 | 2000-09-25 | 알프레드 엘. 미첼슨 | 광학적 전송물질 및 결합재 |
| SE9701144D0 (sv) | 1997-03-27 | 1997-03-27 | Pharmacia & Upjohn Ab | Novel compounds, their use and preparation |
| EP0872233A1 (en) | 1997-04-14 | 1998-10-21 | Janssen Pharmaceutica N.V. | Antiretroviral compositions with improved bioavailability |
| AU8532798A (en) | 1997-06-13 | 1998-12-30 | Roland Bodmeier | Compounds which delay the release of active substances |
| EP0957073A1 (en) * | 1998-05-12 | 1999-11-17 | Schwarz Pharma Ag | Novel derivatives of 3,3-diphenylpropylamines |
| SE9803871D0 (sv) * | 1998-11-11 | 1998-11-11 | Pharmacia & Upjohn Ab | Therapeutic method and formulation |
| SE9802864D0 (sv) * | 1998-08-27 | 1998-08-27 | Pharmacia & Upjohn Ab | Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder |
| SK287111B6 (sk) * | 1998-08-27 | 2009-12-07 | Pharmacia & Upjohn Ab | Farmaceutický prípravok obsahujúci tolterodin s regulovaným uvoľňovaním |
| DE19922662C1 (de) * | 1999-05-18 | 2000-12-28 | Sanol Arznei Schwarz Gmbh | Transdermales therapeutisches System (TTS) Tolterodin enthaltend |
| DK1227806T3 (da) * | 1999-11-11 | 2005-10-31 | Pfizer Health Ab | Farmaceutisk præparat indeholdende tolterodin og dets anvendelse |
| DE19955190A1 (de) * | 1999-11-16 | 2001-06-21 | Sanol Arznei Schwarz Gmbh | Stabile Salze neuartiger Derivate von 3,3-Diphenylpropylaminen |
| SE9904850D0 (sv) * | 1999-12-30 | 1999-12-30 | Pharmacia & Upjohn Ab | Novel process and intermediates |
| US6566537B2 (en) * | 1999-12-30 | 2003-05-20 | Pharmacia Ab | Process and intermediates |
| DE10028443C1 (de) | 2000-06-14 | 2002-05-29 | Sanol Arznei Schwarz Gmbh | Verfahren zur Herstellung von 3,3-Diarylpropylaminen, (R,S)- und (R)-4-Phenyl-2-chromanon-6-carbonsäure sowie (R)-4-Phenyl-2-chromanon-carbonsäure-cinchonidinsalz und deren Verwendung zur Herstellung eines rechtsdrehenden Hydroxybenzylalkohols und von pharmazeutischen Zusammensetzungen |
| DE10033016A1 (de) * | 2000-07-07 | 2002-01-24 | Sanol Arznei Schwarz Gmbh | Verfahren zur Herstellung von 3,3-Diarylpropylaminen |
| US20030086972A1 (en) | 2000-08-09 | 2003-05-08 | Appel Leah E. | Hydrogel-driven drug dosage form |
| AR033711A1 (es) | 2001-05-09 | 2004-01-07 | Novartis Ag | Composiciones farmaceuticas |
| US20030027856A1 (en) | 2001-06-29 | 2003-02-06 | Aberg A.K. Gunnar | Tolterodine metabolites |
| GB0117619D0 (en) | 2001-07-19 | 2001-09-12 | Phoqus Ltd | Pharmaceutical dosage form |
| CA2459265A1 (en) | 2001-09-04 | 2003-03-13 | Pfizer Inc. | Affinity-assay for the human erg potassium channel |
| JP2005506323A (ja) | 2001-09-05 | 2005-03-03 | ベクトゥラ・リミテッド | 経口送達用機能性散剤 |
| BR0212824A (pt) | 2001-09-27 | 2004-10-13 | Pharmacia Ab | Composição farmacêutica |
| US6890920B2 (en) | 2001-10-26 | 2005-05-10 | Pharmacia & Upjohn Company | Quaternary ammonium compounds |
| WO2003039464A2 (en) | 2001-11-05 | 2003-05-15 | Pharmacia & Upjohn Company | Antimuscarinic aerosol |
| US20030152624A1 (en) * | 2001-12-20 | 2003-08-14 | Aldrich Dale S. | Controlled release dosage form having improved drug release properties |
| WO2003103637A2 (en) | 2002-01-10 | 2003-12-18 | Ranbaxy Laboratories Limited | Modified release, multiple unit drug delivery systems |
| KR100540035B1 (ko) | 2002-02-01 | 2005-12-29 | 주식회사 태평양 | 다단계 경구 약물 방출 제어 시스템 |
| DE10224107A1 (de) | 2002-05-29 | 2003-12-11 | Gruenenthal Gmbh | Kombination ausgewählter Opioide mit anderen Wirkstoffen zur Therapie der Harninkontinenz |
| ITMI20021329A1 (it) | 2002-06-14 | 2003-12-15 | Recordati Chem Pharm | Nuove ossialchilammine sostituite |
| WO2004019892A2 (en) | 2002-08-30 | 2004-03-11 | Watson Pharmaceuticals, Inc. | Drug delivery system for treating urinary incontinence |
| WO2004031973A1 (en) * | 2002-09-30 | 2004-04-15 | Advent Networks, Inc. | Implementing request/reply programming semantics using publish/subscribe middleware |
| DE10315917A1 (de) * | 2003-04-08 | 2004-11-18 | Schwarz Pharma Ag | Hochreine Basen von 3,3-Diphenylpropylaminmonoestern |
| DE10315878B4 (de) * | 2003-04-08 | 2009-06-04 | Schwarz Pharma Ag | Vorrichtung zur transdermalen Verabreichung von Fesoterodin und Verwendung |
| BRPI0409653A (pt) * | 2003-04-25 | 2006-04-25 | Pharmacia & Upjohn Co Llc | 3,3-difenilpropilaminas (tolterodina) substituìdas com halogênio com atividade antimuscarìnica |
-
1998
- 1998-05-12 EP EP98108608A patent/EP0957073A1/en not_active Withdrawn
-
1999
- 1999-05-11 HU HU0600760A patent/HU230434B1/hu unknown
- 1999-05-11 PL PL99347823A patent/PL195581B1/pl unknown
- 1999-05-11 US US09/700,094 patent/US6713464B1/en not_active Expired - Lifetime
- 1999-05-11 DE DE69902037T patent/DE69902037T2/de not_active Expired - Lifetime
- 1999-05-11 WO PCT/EP1999/003212 patent/WO1999058478A1/en not_active Ceased
- 1999-05-11 CN CNB998060380A patent/CN1207268C/zh not_active Expired - Lifetime
- 1999-05-11 PL PL380733A patent/PL218882B1/pl unknown
- 1999-05-11 JP JP2000548284A patent/JP3929702B2/ja not_active Expired - Lifetime
- 1999-05-11 PT PT99924929T patent/PT1077912E/pt unknown
- 1999-05-11 NZ NZ507487A patent/NZ507487A/xx not_active IP Right Cessation
- 1999-05-11 EP EP02013481A patent/EP1254890A1/en not_active Withdrawn
- 1999-05-11 PL PL380081A patent/PL202489B1/pl unknown
- 1999-05-11 CZ CZ20060029A patent/CZ299721B6/cs not_active IP Right Cessation
- 1999-05-11 CN CNB2005100702999A patent/CN100491336C/zh not_active Expired - Lifetime
- 1999-05-11 TR TR2000/03319T patent/TR200003319T2/xx unknown
- 1999-05-11 CA CA002328920A patent/CA2328920C/en not_active Expired - Lifetime
- 1999-05-11 KR KR1020007012653A patent/KR100599004B1/ko not_active Expired - Lifetime
- 1999-05-11 HU HU0100779A patent/HU226490B1/hu active Protection Beyond IP Right Term
- 1999-05-11 AT AT99924929T patent/ATE220056T1/de active
- 1999-05-11 BR BRPI9910406A patent/BRPI9910406B8/pt not_active IP Right Cessation
- 1999-05-11 AU AU41412/99A patent/AU748057B2/en not_active Expired
- 1999-05-11 DE DE122007000065C patent/DE122007000065I2/de active Active
- 1999-05-11 SK SK1547-2000A patent/SK286052B6/sk not_active IP Right Cessation
- 1999-05-11 ES ES99924929T patent/ES2181443T3/es not_active Expired - Lifetime
- 1999-05-11 IL IL13911099A patent/IL139110A0/xx active Protection Beyond IP Right Term
- 1999-05-11 EP EP99924929A patent/EP1077912B1/en not_active Expired - Lifetime
- 1999-05-11 RU RU2000125813/04A patent/RU2199525C2/ru active Protection Beyond IP Right Term
- 1999-05-11 MX MXPA00011096A patent/MXPA00011096A/es unknown
- 1999-05-11 HK HK02107859.3A patent/HK1046269B/zh not_active IP Right Cessation
- 1999-05-11 DK DK99924929T patent/DK1077912T3/da active
- 1999-05-11 CZ CZ20003774A patent/CZ296605B6/cs not_active IP Right Cessation
-
2000
- 2000-10-17 ZA ZA200005728A patent/ZA200005728B/xx unknown
- 2000-10-17 IS IS5670A patent/IS2044B/is unknown
- 2000-11-10 NO NO20005669A patent/NO326872B1/no not_active IP Right Cessation
-
2004
- 2004-01-27 US US10/766,263 patent/US7230030B2/en not_active Expired - Lifetime
-
2005
- 2005-08-10 US US11/201,756 patent/US7384980B2/en not_active Expired - Fee Related
-
2006
- 2006-10-18 JP JP2006283861A patent/JP4658895B2/ja not_active Expired - Lifetime
-
2007
- 2007-02-20 JP JP2007039857A patent/JP4833884B2/ja not_active Expired - Lifetime
- 2007-09-10 GE GEAP200710260A patent/GEP20084461B/en unknown
- 2007-09-13 NL NL300293C patent/NL300293I2/nl unknown
- 2007-09-14 LU LU91365C patent/LU91365I2/fr unknown
- 2007-10-04 FR FR07C0050C patent/FR07C0050I2/fr active Active
- 2007-10-15 CY CY2007024C patent/CY2007024I2/el unknown
-
2008
- 2008-04-17 US US12/105,016 patent/US7855230B2/en not_active Expired - Fee Related
-
2009
- 2009-07-17 NO NO2009015C patent/NO2009015I2/no unknown
-
2010
- 2010-06-14 US US12/814,982 patent/US7985772B2/en not_active Expired - Fee Related
-
2011
- 2011-06-15 US US13/161,049 patent/US8338478B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4658895B2 (ja) | ３，３−ジフェニルプロピルアミンの新規な誘導体 | |
| EP1251120B1 (en) | Esters derived from (rr,ss)-2-hydroxybenzoate of 3-(2-dimethylaminomethyl-1-hydroxycyclohexyl)phenyl | |
| US20090215809A1 (en) | Crystalline form of a (3s)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use | |
| SK10632003A3 (sk) | Inhibítor príjmu monoamínov | |
| HK1084099B (en) | Derivatives of 3,3-diphenylpropylamines | |
| BRPI9917910B1 (pt) | 3,3-diphenylpropylamine compounds, use of the same, process for the production of phenolic monoesters, process for the preparation of carbonates and carbamates and pharmaceutical composition |